4.5 Article

ATP sensitive potassium channel openers: A new class of ocular hypotensive agents

Journal

EXPERIMENTAL EYE RESEARCH
Volume 158, Issue -, Pages 85-93

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.exer.2016.04.020

Keywords

ATP sensitive potassium channel openers; Glaucoma; Intraocular pressure; Diazoxide; Cromakalim; Nicorandil; Trabecular meshwork; Potassium channel openers

Categories

Funding

  1. National Eye Institutes Research grant [EY 21727]
  2. Minnesota Partnership for Biotechnology and Medical Genomics MNP [12.06]
  3. Translational Project Development Fund TPDF [15.01]
  4. Mayo Foundation, Rochester, MN
  5. Research to Prevent Blindness, Inc., New York, NY (Department of Ophthalmology, Mayo Clinic)

Ask authors/readers for more resources

ATP sensitive potassium (K-ATP) channels connect the metabolic and energetic state of cells due to their sensitivity to ATP and ADP concentrations. K-ATP channels have been identified in multiple tissues and organs of the body including heart, pancreas, vascular smooth muscles and skeletal muscles. These channels are obligatory hetero-octamers and contain four sulfonylurea (SUR) and four potassium inward rectifier (K-ir) subunits. Based on the particular type of SUR and K-ir present, there are several tissue specific subtypes of K-ATP channels, each with their own unique set of functions. Recently, K-ATP channels have been reported in human and mouse ocular tissues. In ex vivo and in vivo model systems, K-ATP channel openers showed significant ocular hypotensive properties with no appearance of toxic side effects. Additionally, when used in conjunction with known intraocular pressure lowering drugs, an additive effect on IOP reduction was observed. These K-ATP channel openers have also been reported to protect the retinal ganglion cells during ischemic stress and glutamate induced toxicity suggesting a neuroprotective property for this drug class. Medications that are currently used for treating ocular hypertensive diseases like glaucoma do not directly protect the affected retinal cells, are sometimes ineffective and may show significant side effects. In light of this, K-ATP channel openers with both ocular hypotensive and neuroprotective properties, have the potential to develop into a new class of glaucoma therapeutics. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available